Caspases play a major role in apoptosis, and are considered to be key targets for the development of cytoprotective drugs. Previous studies have shown that irreversible caspase inhibitors are effective at protecting against endotoxic shock and lipopolysaccharide (LPS)/Dgalatosamine liver injury model. This study involves the efficacy evaluation of broad spectrum, irreversible caspase inhibitors in preclinical models of anti-apoptotic therapy. Among the compounds tested, compound 3D significantly improved survival of mice in LPS induces apoptosis and acute lung injury in mice upon oral administration. It also exhibited a dose dependent inhibition of LPS/Dgal induced liver damage with ED 50 of 1.01 mg/kg po, based on alanine aminotransferase activities. Protection from liver damage by compound 3D correlated well with suppression of liver tissue caspase-3 activity and drug levels. These results support further development of compound 3D as a potential anti-apoptotic agent.
INTRODUCTION
Programmed cell death is a highly regulated process involving the systemic disassembly and death of cells 1 . A key enzyme implicated in the apoptotic pathway includes a family of cysteine proteases, identified as caspases, which act in a cascade fashion to activate downstream caspases responsible for cleavage of key cellular substrates required for normal cell homeostasis [2] [3] [4] .
The enzymatic cascade leading to apoptosis can be triggered through an extrinsic and intrinsic pathway. The former is driven by the cytokines such as Fas or TNF-α. There is now large body of data that show that caspase-mediated apoptosis accounts for at least part of cell death associated with variety of disease, such as ischemic stroke 5 , acute respiratory syndrome, neurodegenerative disorder 4 and several liver diseases including alcoholic hepatitis, transplantation, Wilson's disease, and viral hepatitis [6] [7] . Several reports demonstrated that inhibition of caspases protect the liver from apoptosis-associated liver injury in preclinical models. Protypical caspase inhibitors such as ZVAD-FMK were efficacious in many animal models, including α-Fas-and TNF -mediated liver injury [7] [8] . According to literature report, the broadspectrum caspase inhibitors were efficacious in preclinical models suggesting the potential use in the treatment of liver diseases 4 . This indicates caspase-3 an interesting therapeutic target and the search for caspase-3 inhibitors has been a constant attempt by many pharmaceutical companies. In this paper, we evaluated the effect of five NCEs (Chemistry and Preliminary biological results were discussed earlier [9] [10] [11] ) encompass better oral pharmacokinetic along with reasonable potency in the LPS induced endotoxic shock model and one NCE (Compound 3D) was further profiled in LPS/ D-Gal induced liver injury model.
MATERIAL AND METHODS

Reagents and General analytical methods
Caspase-3 substrate N-Acetyl-Asp-GluVal-Asp-7-amido-4-methylcoumarin (A1086), LPS (L2630), D-gal (G1639), pepstatin A, aprotinin, leupeptin, phenylmethylsulfonyl fluoride and other general reagent of analytical grade were obtained from Sigma, St. Louis, MO. IDN6556 was synthesized at Aurigene.
Fluorescence measurements were done using VICTOR2V 96/384 multilabel plate reader (PerkinElmer Life Sciences, MA) at λex=360nm and λem=460nm top readout) in Corning black 96-well flat bottom plates. The enzyme activity was measured at 30ºC after 30 minutes. LC-MS/MS was performed in Multiple Reaction Monitoring mode using Applied Biosystems API 3200 coupled to Agilent Technologies 1100 series HPLC on a reverse phase column (Zorbax Eclipse XDB C18, 50 × 4.6 mm, 5 µm).
Compound selection and screening
Biological screening of compounds as well as their chemical synthesis was based on a focused diversity approach belonging to four different series (indole fluromethylketone, indole difluro & tetrafluro phenoxymethylketone and oxalamide); which has been discussed in detail earlier [9] [10] [11] and summarized in Table 1 (potency as well as DMPK profile of the selected compounds from the above series).
Animals
All experimental procedures used in this study were approved by the institutional animal ethical committee (IAEC) based on the Committee for the Purpose of Control and Supervision on Experiments on Animals (CPCSEA) guidelines. For all the animal experiments, 8-10 weeks old male NMRI/balb-c mice with a body weight range of 25-40g were used. Mice were used for the experiments after one-week acclimatization to standard laboratory conditions, which were fed with standard diet and water ad libitum.
Pharmacodynamic studies Endotoxic shock in the mouse model
Protection from lethal apoptosis induced acute lung injury was evaluated in male NMRI mice (n = 10 per group) using intravenous dose of LPS (from E. Compounds were administered at 1mg/kg po repeatedly at 0, 3, 6 and 9 hours post LPS injection. Three mice from each group were euthanized with isoflurane at 24 hour; lung tissue was harvested and frozen in liquid nitrogen for caspase activity.
Mouse liver apoptosis model
Assessment of protection from LPS (from E. Coli serotype 0111:B4, Sigma, St. Louis, MO) /D-Gal (Sigma, St. Louis, MO) induced liver injury model was performed as described [12, [7] [8] . Male Balb-C mice (n = 7 per group) pretreated (0.5 h before) with either vehicle or 3D at different dose levels (0.1 to 10 mg/kg po) and were administered LPS/D-Gal intraperitoneally (0.2mg/kg, 800mg/kg i.p respectively dissolved in saline). Mice were euthanized with isoflurane at 6 h post LPS/D-Gal injection; Plasma was harvested for measurement of alanine aminotransferase (ALT) and drug levels. Liver tissue was harvested and frozen in liquid nitrogen for caspase activity as well as drug estimation. Plasma ALT level was determined using a standard diagnostic kit (Sigma) and were normalized to control in order to express in-terms of percentage. ED 50 was calculated using Prism 5.1 software.
Caspase activity in lung and liver extracts
Effect of NCEs on lung and liver tissue extract caspase-3 activity was determined as described in Hoglen et al., 2003; Hoglen et al., 2001 7-8 , by measuring the cleavage of the fluorescent substrate (AC-DEVD-AMC). Briefly, tissues were homogenized in ice-cold hypotonic buffer (10mM HEPES, pH 7.4; 42mM KCl;50mM MgCl 2 .6H 2 O) containing 1mM dithiothreitol (DTT), 0.5% (w/v) CHAPS, and a cocktail of protease inhibitors [100mM EGTA, 100mM EDTA, 1mg/ml pepstatin A, 10mg/ml aprotinin, 1mg/ml leupeptin, and 1mM phenylmethylsulfonyl fluoride (PMSF)] and centrifuged at 12,000g for 15 min at 4°C. Protein concentrations of the resulting supernatant suspension were determined Bradford's method with bovine serum albumin as the standard. The substrate cleavage activity was measured under similar conditions as mentioned earlier 9 .
Data fitting and statistical analysis
Curve fitting was performed with Prism 5.1 software (GraphPad, San Diego, CA), using builtin equation describing corresponding data models. All the other data were mentioned as mean ± standard deviation. Survival data is shown as Kaplan-Meier survival curves with statistical analysis by log-rank test. Difference in values were considered significant if P<0.05.
RESULTS AND DISCUSSION
Excess apoptosis, which appears to be a detrimental process in a number of diseases including g acute respiratory syndrome and several liver disease such as Wilsons disease, viral and alcohol hepatitis [12] [13] [6] [7] [8] . Caspase play an important role in different pathophysiological conditions and specific inhibition is expected to be therapeutically valuable [13] [14] [15] [16] [17] . Towards identifying inhibitors of caspases with desirable selectivity, ADME and efficacy profile; we screened a focused library of compounds and identified inhibitors from four chemical series that are distinct from other known small molecule caspase-3 inhibitors 9 . Table 1 shows profile of selected set of compounds from 3 series which exhibited better oral exposure were tested in rapid mice model of endotoxic shock along with the reported caspase inhibitor IDN6556 [7] [8] . Male NRMI mice (n = 10 per group) were administered LPS (30mg/kg iv) and survival was monitored for 48 hours in presence and absence of test items. Compound 3D administered by repeat gavage (0, 3, 6 & 9 h post LPS) significantly improved survival ( Figure 1A ; P<0.05 log rank test) compare to other NCEs. It also suppresses the caspase-3 activity in lung tissue extract (figure 1B) similar to IDN6556 24 hours post injection. Compound 3D displayed survival advantage despite one log less potency when compare to IDN6556 in biochemical and cellular assay 9 . This may be due to better exposure in central circulation and low tissue partitioning property. Although permeability of all the tested compounds was low, modest cellular activity with compounds 3D may be because of its interaction with efflux pump [9] . Halogen (Cl) substitution on 5 th position along with tetrafluorophenoxy substituent on right hand side of molecule (as in compound 3D) resulted in better oral exposure which in-turn showed advantages in lowering caspase-3 activity and significant improvement in the survival of mice in endotoxic shock model induced by intravenous injection of LPS 5 .
The attractive profile of compound 3D prompted us to test further in a well-established mice model of liver injury 12, 18, [6] [7] [8] . Balb-C mice (n = 7 per grop) were administered LPS/D-Gal (0.2mg/ kg, 800mg/kg i.p respectively) in saline and pretreated (0.5 h before) with either vehicle or compound 3D (0.1 to 10 mg/kg po). Analysis of plasma showed dose dependent inhibition of ALT levels including the increase in exposure in dose dependent manner (refer figure 2A & 3C) . To investigate the effect of compound 3D on caspase activation, caspase-3 activity was measured using a fluorescent substrate in extracts of livers harvested 6 h after dosing. Caspase-3 activity was markedly inhibited upon compound 3D treatment in dose dependent manner (figure 2B) with ED 50 value of 1.01 mg/kg (figure 2C 
tissue extract with dose dependent increase in exposure levels both in plasma and liver. Because of its irreversible nature as well as selectivity over cysteine peotease, compound 3D could offer advantages specifically in better management of potential adverse effects considering that capsase activity is critically needed to maintain cellular homeostasis in normal cells. However, such potential advantages need to be confirmed by additional characterization of compound 3D in safety studies. In conclusion, this study supports the hypothesis that caspase inhibition may protect cells from abnormally large amounts of apoptosis seen in a number of disease states. Continual treatment with a caspase inhibitor may preserve the loss of critical numbers of cells responsible for the development of caspase-mediated cell death. These results support further development of compound 3D as a potential anti-apoptotic agent.
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